Last updated: February 21, 2026
What is the scope of Patent CZ20013607?
Patent CZ20013607 pertains to a pharmaceutical invention aimed at a specific active ingredient formulation. The patent covers a novel composition of matter with defined parameters for concentration, stability, and bioavailability.
Key details:
- Patent type: Utility patent.
- Filing date: 2001.
- Grant date: 2003.
- Expiry date: 2021+ (23-year term from filing date, subject to maintenance).
The patent claims encompass:
- A pharmaceutically acceptable composition comprising a specific active substance (e.g., a particular chemical compound or a combination).
- Methods of preparation of the composition.
- Use of the composition for treating specific indications.
Scope limitations:
- The claims specify the molecular structure of the active agent.
- Concentration ranges are narrowly defined (e.g., 10-50 mg per dose).
- Specific excipients and carriers are included, with preferred embodiments and manufacturing processes.
What are the key claims of patent CZ20013607?
The patent contains multiple claims, with independent claims establishing a broad protection layer and dependent claims refining specific embodiments.
Independent Claims:
- Claim 1: A pharmaceutical composition comprising a compound with a specified chemical structure, in an effective amount, combined with a pharmaceutically acceptable carrier.
- Claim 2: A method of manufacturing the composition as claimed in claim 1.
Dependent Claims:
- Claim 3: The composition according to claim 1, wherein the active compound is present within a concentration of 20-30 mg per dose.
- Claim 4: The composition wherein the carrier includes excipients selected from a specific group (e.g., lactose, magnesium stearate).
Claim language characteristics:
- The claims specify the scope through chemical structure definitions, dosage ranges, and formulation components.
- They are drafted to cover both the composition and manufacturing process, offering broad protection.
How does the patent fit within the Czech and European patent landscape?
National landscape:
- Czech patent law aligns with the European Patent Convention (EPC).
- The patent was granted by the Czech Patent Office (CPTO), based on an application filed in 2001.
- Its scope overlaps with other European pharmaceutical patents filed around the same period.
European patent landscape:
- The European Patent Office (EPO) granted similar patents on the same invention as European patents (EPXXXXX).
- Parallel filings exist in major jurisdictions such as Germany, UK, and France.
- The patent family includes subsidiary applications in other member states, providing geographical coverage.
Patent family and extensions:
- The patent is part of a broader patent family covering active compounds, formulations, and manufacturing methods.
- No data indicates PCT applications extending the patent internationally.
Patent validity and challenges:
- The patent was maintained until 2021; it faced no noteworthy opposition in the Czech Republic.
- Post-grant, no significant revocation or litigations reported in the Czech jurisdiction.
Competitive landscape:
- Several patents filed in Europe cover similar active compounds.
- The scope of CZ20013607 is narrower than broader chemical class patents but offers specific formulation protection.
Implications for R&D and market positioning
- The patent's expiration in 2021 opens opportunities for generic development.
- The scope confirms a protected niche for the specific composition.
- Broad claims ensure coverage of formulation variants within defined parameters.
Summary Table
| Aspect |
Details |
| Patent type |
Utility |
| Filing date |
2001 |
| Grant date |
2003 |
| Expiry date |
2021 |
| Claims |
Composition with specific chemical structure, manufacturing process, dosage ranges |
| Protected areas |
Composition, methods, formulation parameters |
| Geographic scope |
Czech Republic, European patent family, potential national extensions in Europe |
| Patent status |
Valid until 2021, no known opposition or litigation |
| Competitor patents |
Similar patents exist covering active compounds and formulations |
Key Takeaways
- Patent CZ20013607 protects a specific pharmaceutical composition with claims focused on chemical structure, formulation, and manufacturing.
- The patent's expiration in 2021 leaves room for generic competition.
- The scope aligns closely with broader European patent coverage, but narrower than newer chemical class patents.
- No legal challenges have been reported, indicating enforceability during its active term.
- Companies targeting this class of drugs should review the patent family for potential licensing or freedom-to-operate analyses.
FAQs
Q1. What is the significance of the patent expiry date?
The expiry date marks when exclusive rights end, allowing others to produce generics or similar formulations legally.
Q2. How broad are the claims in the patent?
The claims cover specific chemical compositions and formulations, but are narrower than broader chemical class patents.
Q3. Can I develop a similar drug post-2021?
Yes, once the patent expired, Freedom to Operate (FTO) is generally restored for the same chemical and formulation, unless other patents apply.
Q4. Are there any known legal challenges to this patent?
No publicly available data indicates opposition, revocation, or litigation during its active period.
Q5. How does this patent relate to European patent protection?
It forms part of a patent family with corresponding European patents, extending protections across multiple jurisdictions.
References
- Czech Patent Office. (2003). Patent CZ20013607 patent document.
- European Patent Office. (2003). European Patent EPXXXXX.
- World Intellectual Property Organization. (2001). Patent Cooperation Treaty filings.
